Navigation Links
BeneChill's RhinoChill System Receives CE Marking for European Commercial Sale
Date:1/15/2008

SAN DIEGO, Jan. 15 /PRNewswire/ -- BeneChill, Inc., today announced it has received CE Marking for the commercial sale of the RhinoChill System in European Union member countries. The RhinoChill System is a battery-operated, non-invasive, portable, and easy-to-use medical device for rapid therapeutic patient cooling.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080115/LATU002)

"This is an important step for BeneChill," said Denise Barbut, MD, who is founder and CEO of BeneChill. "We've spent the past three years developing RhinoChill. Clinical trials in Europe and elsewhere have demonstrated that RhinoChill decreases temperature in patients requiring cooling therapy. We are very pleased with this market clearance, which will provide medical personnel within the European Union with a user-friendly tool to cool patients rapidly and non-invasively."

The RhinoChill System uses a nasal catheter to deliver a proprietary inert coolant to the nasal cavity to reduce patient temperature. Therapeutic hypothermia (reducing patient temperature to approximately 33 degrees C or 91 degrees F) has been shown to improve survival and neurologic outcome after cardiac arrest. The American Heart Association and the International Liaison Committee on Resuscitation recommend the use of therapeutic hypothermia in comatose survivors of cardiac arrest. Other possible uses of therapeutic hypothermia include stroke and traumatic brain injury.

The RhinoChill System is designed to overcome limitations of other temperature reduction technologies by enabling early and rapid initiation of patient cooling. The battery-operated RhinoChill System does not require a refrigeration unit -- a drawback associated with all existing hypothermia devices.

"RhinoChill is a unique approach to patient cooling," stated BeneChill COO Allan Rozenberg, PhD, at today's announcement. "RhinoChill uses the nasal cavity, which is the body's natural heat exchanger and is in close proximity to the brain."

Dr. Rozenberg also noted that using the nasal cavity enables treatment by non-specialized medical personnel using non-sterile technique in any surrounding, including ambulances, military rescue operations and emergency rooms, as well as general hospital environments.

About BeneChill:

BeneChill is a venture capital funded medical device company based in San Diego, CA. The company is developing products in the therapeutic hypothermia arena with a focus on rapid and non-invasive cooling in the field. The technology has been used in Europe in cardiac arrest patients. For more information about BeneChill, please visit http://www.BeneChill.com.

The RhinoChill System is an investigational device in the United States. The device is limited by United States law to investigational use only.


'/>"/>
SOURCE BeneChill, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Different method of evaluating the urinary tract system reduces radiation dose
2. Lutheran Senior Services Partners with Silverchair Learning Systems to Enhance Employee Training and Education
3. Exempla Healthcare Contracts For Talismans Quality Donor System
4. Heartline(R) Fitness Systems Named to Inc. Magazines Inaugural List of the 5000 Fastest Growing Private Companies in U.S....
5. University of Wisconsin Hospitals and Clinics Complete System-Wide Conversion to Masimo SET Pulse Oximetry Technology
6. Plexus Systems Ranks in Top Third of the 2007 Inc. 5,000 with Three-Year Sales Growth of 226%
7. Document Security Systems (Amex: DMC) Invites You to a Landmark Event
8. Flu Vaccinations Begin on September 29 Maxim Health Systems to Provide 24,000 Flu Shot Clinics Nationwide
9. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
10. American Heart Association Surgical Supplement Journal Report: Appropriate Hospital Discharge System Can Prevent Future Cardiac Events
11. NAMSA Deploys TrackWise Software as its Quality Management System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... Drs. Justin Kolnick, Kara Diamond, ... teaching their patients about the key role this treatment plays in protecting oral health, ... endodontist. To better serve those who need a root canal in White Plains, NY ...
(Date:3/27/2017)... ... March 27, 2017 , ... SyncDog, Inc. , the ... partners LG Business Solutions at ATARC Federal Mobile Computing Summit , March ... provide education and examination into the mobility tools and technology employed by the ...
(Date:3/27/2017)... ... ... The Case Management Society of America (CMSA) will install six new members ... has elected their upcoming President-Elect, Secretary, Treasurer and two Directors to serve on the ... position has also been added to the BOD, per an appointment made by CMSA ...
(Date:3/27/2017)... ... March 27, 2017 , ... Advantexe ... announced the launch of a new research study, The Business Readiness Report. The ... execute that strategy, and the actual success of achieving individual and company goals. ...
(Date:3/27/2017)... ... ... is still in shock after receiving a $2,500 Academic Award from California Casualty . ... , She thinks the coming week is going to be a very joyful for her ... my students.” , The award will allow the 4th grade teacher at Tumwater Hill Elementary ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 27, 2017  Twist Bioscience, a company accelerating science ... that it raised an additional $33 million. To date, ... "It is an exciting time to ... and continue to deliver industry-leading gene volume to our ... Emily M. Leproust, Ph.D., CEO of Twist Bioscience. "We ...
(Date:3/27/2017)... , March 27, 2017  PhaseRx, Inc. (NASDAQ: ... life-threatening inherited liver diseases in children, today reported ... year ended December 31, 2016 and provided an ... "PhaseRx continued to make progress during the fourth ... results from our non-human primate safety study, and with ...
(Date:3/27/2017)... , March 27, 2017 Invivotek, LLC, a ... in vivo pharmacology contract research organization (CRO), ... to its newly expanded preclinical research facility in ... provides a cleaner, renewable energy source to reduce costs ... Completion of the Genesis Solar Farm follows Invivotek,s recent ...
Breaking Medicine Technology: